Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
921-940 of 998 trials

Non-Small Cell Lung Cancer: Cemiplimab and TEDOPI® Study

We are testing a new combination therapy for patients with non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this therapy helps clear cancer markers and improves survival compared to standard treatment.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Major Depressive Disorder: CYB003 Treatment Study

We are studying the effects of a new medication, CYB003, on symptoms of major depressive disorder in adults. This trial compares its effectiveness to a placebo to see if it may help improve mood and quality of life.

Major Depressive Disorder3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Systemic Lupus Erythematosus: CC-97540 CAR T Cell Therapy

We are studying a new CAR T cell therapy for people with active lupus who haven't responded to standard treatments. The goal is to see if it can improve symptoms and overall health.

Systemic Lupus ErythematosusLupus Nephritis>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyRheumatology

UTI Vaccine Study for Adults Aged 18-64

We are testing a new vaccine to see if it can safely prevent urinary tract infections caused by E. coli in adults, especially women. The study will compare its effectiveness to a placebo.

Urinary Tract Infections1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

Endometrial Cancer: Sacituzumab Tirumotecan and Pembrolizumab Study

We are studying a combination of sacituzumab tirumotecan and pembrolizumab for people with advanced or recurrent endometrial cancer. The goal is to see if this combination works better than pembrolizumab alone.

Endometrial CarcinomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncology

PCOS Fertility: Letrozole vs. Gonadotropins

We are studying whether continuing ovulation induction with letrozole is more effective than switching to gonadotropins for women with polycystic ovary syndrome. The trial also looks at safety, quality of life, and costs related to fertility treatment.

Polycystic Ovary Syndrome (PCOS)1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteEndocrinologyGynecology and ObstetricsInternal Medicine

Alopecia Areata: Ritlecitinib Study

We are investigating whether two doses of ritlecitinib can help people aged 12 and older with alopecia areata regrow their scalp hair. The study compares the effects of the medication to a placebo.

Alopecia Areata6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Glioblastoma: Adding Zoledronic Acid to Treatment

We are studying whether adding zoledronic acid to standard chemotherapy can help improve survival and treatment response in patients with glioblastoma. We also want to assess its safety and tolerability.

Glioblastoma3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Severe Asthma: Verekitug (UPB-101) Study

We are studying the long-term safety and effects of verekitug in adults with severe asthma. This research aims to see how it helps manage asthma attacks and improve breathing.

Severe Asthma1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyPulmonology

Bowel Dysfunction After Rectal Cancer Surgery: Irrigation vs. Suppositories

We are comparing transanal irrigation and glycerol suppositories to see which treatment better improves bowel function and quality of life for patients after rectal cancer surgery.

Low Anterior Resection Syndrome≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Microscopic Colitis: SAR444336 Treatment Study

We are investigating a new treatment, SAR444336, for adults with microscopic colitis in remission. The study aims to see if it can effectively manage symptoms without steroids and evaluate its safety.

Microscopic Colitis6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

Alzheimer's Disease: NPI-001 Study

We are testing a new oral medication, NPI-001, for people aged 50 to 85 with Mild Cognitive Impairment or mild dementia due to Alzheimer's. The study aims to assess its safety and effects on brain health and cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsStandard MedicinesPartially RemoteInternal MedicineNeurology

Insomnia in Adolescents: Melatonin vs. Quetiapine

We are studying whether melatonin or low-dose quetiapine can improve sleep in adolescents with psychiatric disorders and insomnia. We’ll also look at how these treatments affect overall well-being and daily functioning.

Psychiatric Disorders and Insomnia≤3 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Knee Surgery: Testing SRSD107 for Blood Clot Prevention

We are studying whether SRSD107 can effectively prevent blood clots in adults undergoing knee replacement surgery. We will also assess how safe it is compared to the standard treatment, enoxaparin.

Venous Thromboembolism6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyOrthopedics and Traumatology

GSK4418959 for Solid Tumors: A New Treatment Approach

We are investigating the safety and early effectiveness of the DNA-repair inhibitor GSK4418959 in adults with specific solid tumors. This study looks at the drug alone and with other cancer treatments to see how well it works.

Colorectal Cancer3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Tebapivat Study

We are investigating a new medication, tebapivat, to see if it helps improve anemia in people with sickle cell disease. The study will also look at its safety and effects on fatigue and pain.

Sickle Cell Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Gastric Cancer: Zolbetuximab with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for adults with advanced gastric cancer to see if it works better than standard therapies. This trial is for patients with specific tumor markers.

Gastric CancerMetastatic Gastric CancerGastroesophageal Junction AdenocarcinomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Anal High-Grade Lesions: Sinecatechins Ointment

We are studying whether adding a topical ointment to standard treatment helps patients with high-grade anal lesions achieve better results. The goal is to see if it reduces lesions and prevents recurrence.

Anal High-Grade Squamous Intraepithelial Lesions (HSIL)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Atopic Dermatitis: Long-term Study of APG777

We are examining the long-term safety and effectiveness of APG777 in patients with moderate-to-severe atopic dermatitis who have already used this treatment. The goal is to see how well it works over time and if it remains safe.

Atopic DermatitisEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Narcolepsy and Idiopathic Hypersomnia: ALKS 2680 Study

We are investigating the safety and tolerability of ALKS 2680 for people with narcolepsy and idiopathic hypersomnia. The study also looks at its effects on excessive daytime sleepiness and cataplexy.

Narcolepsy and Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology